Compositions emitting positrons and containing inorganic particles, and use thereof in medicine, especially for diagnostic processes

摘要

The invention relates to pharmaceutical agents containing a particulate inorganic matrix having a diameter of from 0.1 nm to 100 μm, preferably 1 nm to 10 μm, particularly preferably 1 nm to 1 μm, such as, for example, topaz, (Al2F2)[SiO4], and chiolite, Na[Al3F4], preferably wavellite, Al3(PO4)2(OH,F)2, calcium carbonate, CaCO3, maghemite, γ-Fe2O3, particularly preferably zeolites, gen. formula Mn[(AlO2)x(SiO2)y] (M=metal, e.g. Na), magnetite, Fe3O4, and barium sulphate, BaSO4, and very particularly preferably gallium phosphate, GaPO4, apatite or fluorohydroxyapatite, Ca5(PO4)3(OH,F)=3Ca3(PO4)2*Ca(OH,F)2, and fluorspar, CaF2, which, in addition to the natural isotope distribution of the structure type-forming elements of the anions and cations, also contain medically usable contents of positron-emitting nuclides, such as, for example, [15]O, [30]P, [13]N, preferably [65]Ga, [11]C, particularly preferably [13]Ba, [26]Al, and very particularly preferably [68]Ga and [18]F, the preparation thereof, and the use of these composition in medicine, particularly preferably in diagnostic imaging, in particular positron emission tomography (PET), on animals and humans, and in vitro diagnostics.

主权项

1. A pharmaceutical agent containing a particulate inorganic matrix, which in addition to the natural isotope distribution of the structure type-forming elements of anions or cations, contains contents of positron-emitting nuclides, wherein at least some of the positron-emitting nucleotides form part of the matrix,
wherein the structure type forming elements comprise amorphous structures or a mixture of amorphous structures and crystal structures, wherein the number of positron-emitting nuclides per particulate inorganic matrix is greater than or equal to 1, wherein the particulate inorganic matrix is selected from the group consisting of topaz (Al2F2)[SiO4], chiolite Na[Al3F4], wavellite Al3(PO4)2(OH,F)2, calcium carbonate (CaCO3), maghemite (γ-Fe2O3), zeolites, magnetite (Fe3O4), barium sulphate (BaSO4), gallium phosphate (GaPO4), apatite or fluorohydroxyapatite (Ca5(PO4)3(OH,F)=3Ca3(PO4)2*Ca(OH,F)2) and fluorspar (CaF2), wherein the particulate inorganic matrix is coupled to a target-specific ligand and wherein the positron-emitting nuclides are selected from the group consisting of [15]O, [30]P, [13]N, [65]Ga, [11]C, [131]Ba, [26]Al, [68]Ga and [18]F.